For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Rate of Kidney Function Decline in Older Adults: A Comparison Using Creatinine and Cystatin CShlipak M.G.a · Katz R.b · Kestenbaum B.c · Fried L.F.d · Newman A.B.e · Siscovick D.S.f · Stevens L.g · Sarnak M.J.g
aGeneral Internal Medicine Section, San Francisco VA Medical Center and Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, Calif., bCollaborative Health Studies Coordinating Center, Department of Biostatistics, University of Washington, and cNephrology Division, University of Washington, School of Medicine, Seattle, Wash., dRenal Section, Medical Service, VA Pittsburgh Healthcare System, and eDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health and the Division of Geriatric Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa., fDepartments of Medicine and Epidemiology, University of Washington, Seattle, Wash., and gDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Mass., USA Corresponding Author
Michael G. Shlipak, MD, MPH
General Internal Medicine Section, VA Medical Center (111A1)
4150 Clement Street
San Francisco, CA 94121 (USA)
Tel. +1 415 750 2093, Fax +1 415 379 5573, E-Mail firstname.lastname@example.org
Background/Aims: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. Methods: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 ± 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m2). Results: Mean annual eGFR loss as estimated from creatinine was 0.4 ± 3.6 ml/min/1.73 m2, with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 ± 2.6, with 25% of the participants experiencing a rapid decline (p < 0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n = 263) using creatinine and 19% (n = 544) using cystatin C (p < 0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16–1.65), 1.62 (1.31–1.99) and 2.96 (2.28–3.84) for participants aged 70–74, 75–79 and 80+ at baseline, compared with those aged 65–69. Conclusion: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research.
© 2009 S. Karger AG, Basel
Impaired kidney function is highly prevalent in the elderly and is a risk factor for cardiovascular disease, adverse health outcomes and death. Because kidney function is a major determinant of health in the elderly, it is important to understand the expected rate of change in kidney function. However, the rate at which kidney function declines in elderly persons and the independent effects of age, sex and race have not been conclusively studied. Based on findings using creatinine clearance among a healthy, predominately white cohort (Baltimore Longitudinal Study of Aging), age-related decline in glomerular filtration rate (GFR) is generally believed to be less than 1 ml/min/1.73 m2 each year . To understand longitudinal changes in kidney function among elderly persons, we ideally would use a ‘gold standard’ measure of GFR across many years of follow-up. Unfortunately, few studies have directly measured GFR in elderly persons, and none have repeated GFR measurements after several years of follow-up. The use of endogenous filtration markers, particularly creatinine, to estimate declines in kidney function is thus the current standard for clinical practice and research.
Creatinine-based measurements of kidney function, however, may be limited as a tool to estimate either the rate of kidney function change in the elderly or the effects of age, sex and race. Since creatinine is a breakdown product of muscle, serum creatinine levels are directly associated with muscle mass. Muscle mass is lower in older persons, women and whites on average, which complicates the interpretation of creatinine changes over time. Equations to estimate GFR from creatinine make the inherent assumption that the effects of age, sex and race on the creatinine-GFR relationship are constant over time. Cystatin C is an alternative serum marker of kidney function that appears less biased for measuring kidney function in the elderly. Prior studies using cystatin C in older persons demonstrated its greater prognostic ability compared with creatinine or creatinine-based estimated GFR (eGFR) for predicting adverse outcomes [2,3,4,5,6,7]. Yet, no study has evaluated changes in kidney function over time using cystatin C, or compared such changes with estimates based on creatinine.
In the Cardiovascular Health Study (CHS), we serially measured cystatin C and creatinine. We recently found that participants with rapid declines in eGFR (>3 ml/min/1.73 m2 per year), based on either creatinine or cystatin C, had substantially elevated mortality risks during follow-up independent of baseline kidney function and other comorbidities . In this paper, we compared changes in kidney function over 7 years of follow-up using GFR estimates based on creatinine and cystatin C. In addition, we evaluated the associations of age, sex and race (white or black) on kidney disease progression.
The CHS is a community-based longitudinal study of adults who were 65 years of age or older at baseline . A main cohort of 5,201 participants was recruited between 1989 and 1990 from 4 US communities (Sacramento County, Calif., USA; Forsyth County, N.C., USA; Washington County, Md., USA; Allegheny County, Pa., USA) . An additional 687 African-Americans were recruited in 1992 and 1993. The baseline visit for these additional participants was the year 3 visit for the original cohort. Eligible participants were sampled from Medicare eligibility lists in each area. Subjects were excluded if they were institutionalized, required a proxy to give consent, were planning to move out of the area within 3 years after recruitment, required a wheelchair in the home, were receiving hospice care, or were undergoing radiation or chemotherapy for cancer.
Institutional review board approval for the data collection procedures of the CHS was obtained at each of the 4 clinical sites and at the Data Coordinating Center (University of Washington). In addition, we obtained institutional review board approval for this study from Tufts-New England Medical Center and the University of California, San Francisco, Calif., USA.
Participants were included if they had at least 2 measurements of kidney function using both creatinine and cystatin C (n = 4,380; 2,396 participants had 3 measurements of kidney function and 1,984 participants had 2 measurements; 1,452 had only 1 measurement of kidney function). Cystatin C was measured from frozen samples that were collected at visits from 1989–1990 (baseline), 1992–1993 (3rd year of follow-up) and 1996–1997 (7th year of follow-up) using a BNII nephelometer (Siemens; Deerfield, Ill., USA) . The year 3 measurements were conducted in 2003, and the baseline and year 7 measurements in 2006. All measurements used the same equipment in the same laboratory. Cystatin C remained stable through five cycles of freeze/thaw . We estimated GFR from cystatin C using an equation developed from the pooling of several cohorts with GFR measured from iothalamate (eGFR = 76.7 ×cysC–1.18) . As a sensitivity analysis, we repeated the analyses using 100/cystatin C as the index of kidney function, as used in prior literature .
Serum creatinine was assayed by a colorimetric method (Ektachem 700, Eastman Kodak) from frozen sera. We estimated GFR with the use of the 4-variable version of the Modification of Diet in Renal Disease equation [GFR = 186.3 × (serum creatinine–1.154) × (age–0.203) × 1.212 (if black) × 0.742 (if female)], updating age for each creatinine measurement . Results were very similar when age was held constant through the analyses. Creatinine concentrations were indirectly calibrated to the reference laboratory at the Cleveland Clinic, as previously described .
Age, sex and race were the primary predictors in this analysis. Additional predictors of kidney decline were used for adjustment in multivariate analysis. These included prevalent cardiovascular disease [heart failure[, ]coronary heart disease (myocardial infarction, angina, revascularization), stroke and transient ischemic attack], hypertension, diabetes mellitus (defined by use of an oral hypoglycemic agent, insulin or a fasting glucose level ≥126 mg/dl), body mass index, smoking history (former vs. never, current vs. never), and fasting levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Models were similar when systolic or diastolic blood pressure measurements were used.
We compared the characteristics of participants with and without at least 2 measurements of kidney function. Among participants with multiple measurements, characteristics of white women, black women, white men and black men were compared by ANOVA and a χ2 test as appropriate.
As the length of follow-up varied among participants, change in kidney function was determined by linear regression as the slope per year for each individual. Mixed models were used in supplementary analyses, which produced identical results. We confirmed that the annual rate of increase in creatinine and cystatin C was equivalent across each time interval. We compared the distribution of the rates of decline using GFR estimated from creatinine (eGFRcrea) and GFR estimated from cystatin C (eGFRcys), and determined the proportions with a net decline in eGFR, a rate of decline >1 and >3 ml/min/1.73 m2/year. A rate of decline >3 ml/min/1.73 m2/year was defined as ‘rapid kidney decline’ based on prior studies and its concurrence with the high quartile of eGFRcys decline [8,16,17,18]. This rate of kidney function decline was associated with higher rates of mortality during subsequent follow-up in CHS, whereas no association was observed below the threshold of 3 ml/min/year .
We compared the annual rates of kidney function decline across age categories (65–69, 70–74, 75–79, >80 years) and among the 4 sex/race categories. We created linear regression models that modeled the annual rate of change in eGFRcrea or eGFRcys as the dependant variable in separate models adjusted for the covariates listed above. Sidak-adjusted tests for significance were used to evaluate differences in mean levels among sex and race groups . Multivariate logistic regression was used to evaluate age, sex and race as independent predictors of the dichotomized outcome: rapid kidney function decline.
Among participants without chronic kidney disease (CKD; eGFR >60 ml/min/1.73 m2) at the baseline visit, we compared the incidence of CKD (eGFR <60 ml/min/1.73 m2) at the final measurement of kidney function using creatinine and cystatin C. In these analyses, baseline CKD and incident CKD were determined separately using creatinine and cystatin C. In addition, the incidence of eGFR <45 ml/min/1.73 m2, which has been referred to as stage 3B CKD , was also compared using creatinine and cystatin C. Incidence of end-stage renal disease (ESRD) was too low during follow-up to evaluate this outcome. As a sensitivity analysis, we evaluated the combined outcome of ‘death or CKD’ to capture participants who died prior to having a second measurement of kidney function. The associations of eGFRcrea and eGFRcys with this combined endpoint were compared.
S-Plus (release 8.0; Insightful Inc., Seattle, Wash., USA) and SPSS statistical software (release 220.127.116.11; SPSS Inc., Chicago, Ill., USA) were used for the analyses. p < 0.05 was considered statistically significant.
Compared with participants with 0–1 measurements of kidney function, those with at least 2 measurements of kidney function were younger (72 vs. 76 years), more likely to be white (86 vs. 77%), female (60 vs. 52%) and had lower creatinine levels at baseline (0.93 ± 0.30 vs. 1.07 ± 0.61 mg/dl) (p for all comparisons <0.001). Among participants with 0–1 measurements, 51% had died prior to the 1996–1997 clinical visit when the last kidney function measurement was to be attained.
Among participants with at least 2 measurements of creatinine and cystatin C, 2,234 were white women, 376 were black women, 1,561 were white men and 209 were black men. Average age was approximately 72 years in each subgroup. Cardiovascular risk factors, prevalent cardiovascular disease and measurements of kidney function differed across the sex/race subgroups (table 1). Baseline levels of cystatin C were the highest, and eGFRcys the lowest, among white men, but were similar among the other 3 groups. Serum creatinine levels were higher in black men than in white men, and higher in black women than in white women; however, black participants had higher eGFRcrea than whites.
At baseline, the mean eGFRcrea and eGFRcys levels were the same for the cohort overall (79 ± 23 and 79 ± 19, respectively) and within each demographic subgroup (table 1). At the final kidney measure, the mean eGFRcrea was higher than eGFRcys (78 ± 23 vs. 70 ± 19 ml/min/1.73 m2, p < 0.001). The difference between the final eGFR estimates based on creatinine and cystatin C varied from 6 ml/min/1.73 m2 in black women to 12 ml/min/1.73 m2 in white men.
The distribution of annual change in eGFR for the cohort differed greatly when comparing the equations based on creatinine and cystatin C (fig. 1). The distribution of annual eGFRcrea change appeared normal and centered near the origin. Thirty-nine percent of the cohort had a positive slope of eGFRcrea (improved kidney function over time). The mean annual change of eGFRcrea was a decline of 0.4 ± 3.6 ml/min/1.73 m2. Thirty-two percent had a net annual decline ≥1 ml/min/1.73 m2/year, and 16% had a decline ≥3 ml/min/1.73 m2/year. The distribution of annual change in eGFRcys also appeared normal, but only 20% had a positive slope. The mean change was an annual decline of 1.8 ± 2.6 ml/min1.73 m2. Sixty-two percent had an annual decline ≥1 ml/min1.73 m2 and 25% had a decline ≥3 ml/min1.73 m2 (p < 0.001 for both comparisons with eGFRcrea). When we used 100/cystatin C to estimate GFRcys, the mean annual decline was 2.0 ± 2.9 ml/min.
The rate of loss in kidney function appeared to accelerate among older participants. The annual decline in eGFRcrea ranged from 0.1 (0.09) ml/min/1.73 m2 in the 65–69 age group to 0.8 (0.18) ml/min/1.73 m2 among those over 80 years (p < 0.001). Kidney function loss by eGFRcys also appeared to increase with advancing age, ranging from 1.6 (0.06) ml/min/1.73 m2/year in the 65–69 age group to 2.2 (0.13) ml/min/1.73 m2/year among those over 80 years (p < 0.001). The association of age with rate of kidney function decline was essentially unchanged after multivariate adjustment.
The annual change in creatinine and eGFRcrea was compared across subgroups defined by race and sex. The mean annual changes (±SD) in creatinine were 0.01 ± 0.07 mg/dl in white women, 0.02 ±0.11 mg/dl in black women, 0.002 ± 0.06 mg/dl in white men and 0.006 ± 0.63 mg/dl in black men (p < 0.001). Rates of eGFRcrea change by sex and race subgroups are shown in figure 2. After multivariate adjustment, female sex was associated with a 0.5 ml/min/1.73 m2 greater annual decline in eGFRcrea (p < 0.001), but race was not a significant predictor (p = 0.10). In contrast, annual loss of eGFRcys did not differ significantly by sex or race, varying only from –1.7 ± 2.4 ml/min/1.73 m2/year in white women to –2.1 ± 3.5 ml/min/1.73 m2/year in black men (fig. 2). Multivariate adjustment for age, risk factors and baseline kidney function decreased these differences: –1.8 ml/min/1.73 m2/year (95% CI: –1.9, –1.6) for white women, –1.7 ml/min/1.73 m2/year (95% CI: –2.0, –1.3) for black women, –1.9 ml/min/1.73 m2/year (95% CI: 2.1, –1.7) for white men and –1.9 ml/min/1.73 m2/year (95% CI: –2.4, –1.4) for black men. The adjusted rate of change in cystatin C concentration was 0.03 mg/l/year in all 4 subgroups. The annual rate of change in 100/cystatin C ranged from –1.9 ± 2.7 in white women to –2.4 ± 3.9 in black men (p > 0.20).
A rapid rate of decline was observed in 714 (16%) participants based on eGFRcrea and 1,083 (25%) participants based on eGFRcys. We compared the overlap of participants with rapid decline by eGFRcrea and eGFRcys (fig. 3). Rapid decline by eGFRcrea detected 39% of the 1,083 participants with rapid decline by eGFRcys. Conversely, rapid decline by eGFRcys detected 59% of the 714 participants with rapid eGFRcrea decline. The mean eGFRcrea and eGFRcys declines were 5.8 and 1.0 ml/min/1.73 m2/year in persons with only eGFRcrea rapid decline, 0.1 and 4.4 in persons with only eGFRcys decline and 6.2 and 5.9 among participants with rapid decline by both measures.
After multivariate analysis, increased age was strongly and incrementally associated with rapid decline in kidney function based on either eGFRcrea or eGFRcys (table 2). Race was not a predictor in either analysis. In the eGFRcrea analysis, men had only half the risk of women for rapid kidney decline, whereas sex was not associated with rapid kidney decline based on eGFRcys.
Among participants without CKD (eGFR >60 ml/min/1.73 m2) at the initial visit, we compared the proportion who developed incident CKD (eGFR <60) at the final kidney function measurement (year 7). Using eGFRcrea, 10% (n = 263) had developed CKD at the year 7 measurement of kidney function. The proportion with new CKD was nearly 2-fold when measured by cystatin C, making up 19% of the participants (n = 544, p < 0.001 for difference with eGFRcrea). Similarly, the proportion that reached eGFR <45 was twice as high when kidney function was measured by cystatin C; making up 2% of the participants (n = 50) by eGFRcrea versus 4% (n = 103) by eGFRcys (p < 0.001). We also compared eGFRcrea and eGFRcys with the combined endpoint of ‘death or CKD’. Each 5 ml/min/1.73 m2 lower eGFRcys had significantly higher adjusted odds (1.29; 1.24–1.33) of the combined outcome. The association per 5 ml/min/1.73 m2 lower eGFRcrea was significant, but weaker (1.04; 1.02–1.06).
In this community-based cohort of older individuals, we observed substantial differences in the rates of kidney function decline using creatinine versus cystatin C based estimates of GFR. When using the Modification of Diet in Renal Disease creatinine equation, we observed an annual eGFR decline of only 0.4 ml/min/1.73 m2 over 7 years of follow-up, far less than the expected rate of decline . The rate of eGFRcrea decline was substantially greater in women than men. In contrast, the cystatin C-based eGFR measure declined annually by 1.8 ml/min/1.73 m2, which was more than 4-fold the rate of eGFRcrea, and did not differ by sex or race. Increasing age independently predicted more rapid rates of both eGFRcrea and eGFRcys decline. The proportion of participants identified as ‘rapid decliners’ (annual loss of GFR >3 ml/min/1.73 m2) was 50% higher when using eGFRcys compared with eGFRcrea, and eGFRcys detected twice the incidence of CKD during follow-up compared with eGFRcrea. Because participants with rapid kidney decline in this cohort had a higher mortality risk , we believe that eGFR changes detected by either creatinine or cystatin C are clinically meaningful.
The most striking finding from our study was how different the eGFR slopes were when based on creatinine or cystatin C. We believe that the differences are most likely caused by creatinine’s insensitivity for detecting relatively small changes in GFR in elderly persons. Creatinine generation decreases with age, and likely is even further reduced in persons with accelerated kidney function decline, as these individuals have greater impairments in diet and physical activity. Unfortunately, no study has directly measured GFR in a large cohort of elderly persons, much less repeat GFR measurements several times during follow-up. Therefore, we cannot conclude that either the creatinine or cystatin C measurements are more accurate. In the absence of such a study, clinical research (like clinical practice), must rely on indirect estimates of GFR using endogenous filtration markers. Our prior research comparing associations of creatinine and cystatin C with longitudinal outcomes suggests to us that cystatin C may have a greater ‘signal-to-noise ratio’ than creatinine. In addition, a small cohort of persons with type-2 diabetes and normal GFR levels found that eGFRcys changed over time in close proximity with measured iothalamate GFR, whereas eGFRcrea depicted a falsely slow rate of decline . Furthermore, the eGFRcrea rates of decline in our study were much lower than expected based on prior studies of the elderly [1, 2, 4]. Hopefully a future study will measure GFR longitudinally in elderly persons to help us distinguish the relative accuracy and precision of creatinine and cystatin C in this population.
If our data are able to be generalized and cystatin C does capture unrecognized CKD, these results could have substantial public health importance. Based on NHANES 1999–2002, the elderly population (65+) in the United States was 36 million, of whom 28 million did not have CKD. Assuming 9% develop unrecognized CKD during a 7-year follow-up, then 2.5 million (350,000/year) could be detected by serial measurements of cystatin C, but not creatinine. Whether or not this ‘early detection’ strategy would improve patient outcomes is a question for future research.
In this study, the association of sex with kidney function decline differed between analyses based on eGFRcrea and eGFRcys; women had a greater decline in eGFRcrea than men, but equivalent declines in eGFRcys. Although no prior studies have addressed this research question using cystatin C, 2 studies that used iothalamate GFR in CKD cohorts, the Modification of Diet in Renal Disease and the African-American Study of Kidney Disease and Hypertension studies, found no association of sex with progression [21, 22]. Among studies that evaluated longitudinal changes in kidney function by creatinine-based measurements, 8 studies found no independent differences by sex, whereas 6 found a faster progression among men [16, 23, 24]. A sex-based comparison of the longitudinal associations of eGFRcys declines with health outcomes would be helpful for determining the relative prognostic utility of cystatin C among men and women.
The incidence of ESRD in the United States is substantially higher among blacks of all ages compared with whites; yet black and white participants had similar rates of kidney function decline in this study, based on creatinine or cystatin C. Although race did not predict rapid decline by either measurement, eGFRcys detected a greater proportion of black participants with rapid decline of kidney function. Two prior studies in non-CKD cohorts also found no association of race with kidney function decline [25, 26], whereas a study of nondiabetic CKD found a faster rate of progression among blacks . A United States population analysis found that blacks and whites have a similar prevalence of CKD, but that blacks have faster progression from CKD to ESRD . Future studies should evaluate whether the measurement of cystatin C adds useful information for understanding racial disparities in kidney disease.
This study has additional limitations beyond the absence of a ‘gold standard’ for GFR measurements. Many subjects in the CHS had only 1 measurement of kidney function as they died or were otherwise unable to provide adequate sera for a repeat measurement. The absence of these subjects could have biased our results toward an underestimate of kidney function decline by either measure, as the excluded subjects had higher baseline creatinine and worse comorbidity. Both GFR estimating equations used in this study were derived from cohorts that were predominately comprised of nonelderly persons with CKD [12, 28]. At this time, we do not have GFR estimating equations that have been validated in either elderly persons or in populations without kidney disease. However, the observed differences in eGFRcrea and eGFRcys in this study are attributable to the much larger relative change over time in cystatin C compared with creatinine. Furthermore, less than 15% of our cohort was African-American, and we did not have any Asian or Hispanic participants.
In conclusion, GFR estimates from cystatin C indicated a more than 4-fold rate of decline and a 2-fold incidence of CKD compared with creatinine-based estimates. We also found twice the annual rate of GFR decline in elderly persons than had been reported in prior literature. Given the growing burden of CKD and ESRD, determination of the optimal method for GFR estimation in the elderly, whether by creatinine, cystatin C or a combination of both, should be a high priority for future research.
This work was supported by contracts R01 HL073208-01 and R01 DK066488 from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases, respectively. In addition, this work was supported by the American Federation for Aging Research by a Paul Beeson Scholars Program award and R01AG027002 and K24DK078204-01 from the National Institutes of Health. The CHS is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, and N01 HC-15103 from the NHLBI. This study was funded through contracts with the NHLBI and included substantial NHLBI involvement in data collection, analysis and interpretation, as well as manuscript preparation. A full list of participating CHS investigators and institutions can be found at http://www.chs-nhlbi.org.
Michael G. Shlipak, MD, MPH
General Internal Medicine Section, VA Medical Center (111A1)
4150 Clement Street
San Francisco, CA 94121 (USA)
Tel. +1 415 750 2093, Fax +1 415 379 5573, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.